ID   MCF10A-ERBB2m-12
AC   CVCL_C7R0
SY   MCF10A-ERBB2_type-13; 06M15014
DR   CancerTools; 161201
DR   Wikidata; Q117704671
RX   PubMed=30787176;
WW   https://www.fmu.ac.jp/home/trc/en/contract-research-provision/human-gene-overexpressing-cell-lines/
CC   Part of: Fukushima Translational Research Project gene-overexpressing cell lines panel.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transduction; Gene=HGNC; HGNC:3430; ERBB2 (Note=With p.Arg896Cys (c.2686C>T)).
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) (HygR).
CC   Derived from site: In situ; Breast, epithelium; UBERON=UBERON_0008367.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0598 ! MCF-10A
SX   Female
AG   36Y
CA   Spontaneously immortalized cell line
DT   Created: 21-03-23; Last updated: 19-12-24; Version: 4
//
RX   PubMed=30787176; DOI=10.1158/1535-7163.MCT-18-1085;
RA   Irie H., Ito K., Fujioka Y., Oguchi K., Fujioka A., Hashimoto A.,
RA   Ohsawa H., Tanaka K., Funabashi K., Araki H., Kawai Y., Shimamura T.,
RA   Wadhwa R., Ohkubo S., Matsuo K.;
RT   "TAS0728, a covalent-binding, HER2-selective kinase inhibitor shows
RT   potent antitumor activity in preclinical models.";
RL   Mol. Cancer Ther. 18:733-742(2019).
//